PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-23.20%
Negative net income growth while VET stands at 8.36%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.21%
Less D&A growth vs. VET's 9.41%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
-66.67%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-230.43%
Both cut yoy SBC, with VET at -25.84%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
19.38%
Slight usage while VET is negative at -151.08%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
-52.86%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
29.57%
Some yoy usage while VET is negative at -151.08%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-2600.00%
Negative yoy while VET is 19.84%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
105.66%
Some CFO growth while VET is negative at -25.31%. John Neff would note a short-term liquidity lead over the competitor.
-4.01%
Negative yoy CapEx while VET is 39.23%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
286.05%
Acquisition growth of 286.05% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
4.01%
Purchases growth of 4.01% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-56.36%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-4.01%
Both yoy lines negative, with VET at -267.35%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
19.64%
Investing outflow well above VET's 21.25%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-50.00%
We cut debt repayment yoy while VET is 6.58%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.